For the quantitative determination of small molecule, peptide and macromolecule therapeutics in support of pharmacokinetic (PK) studies.
including permeability, metabolic stability, metabolite identification (cold & radiolabeled), and in vitro drug-drug interaction risk assessment, ranging from highly automated discovery screening platforms to definitive development studies that enable regulatory submission.
Including quantitative determination of large molecule therapeutics using ligand binding assays technologies in support of pharmacokinetic (PK) studies and immunogenicity assays assessments for pre-clinical and clinical studies including tier based approaches, neutralizing assays, and isotyping assays.
ncluding quantitative determination of large molecule therapeutics using ligand binding assays technologies in support of pharmacokinetic (PK) studies and immunogenicity assays assessments for pre-clinical and clinical studies including tier based approaches, neutralizing assays, and isotyping assays.
Indianapolis, IN, USA |
|
Ithaca, NY, USA |
|
RTP, NC, USA |
|
Beijing, China |
|
We not only have the technology, systems, and processes to support your routine and complex projects, but we have 30+ years of experience and industry leading knowledge to provide key insights into the development of your product.
We can also help you develop methods for detecting your small and large molecule therapeutics, and to provide industry leading assays for immunogenicity assessments. The result is reliable, high-quality data for better decision-making, faster, more efficient drug development, and higher quality regulatory submissions.